FDA · United States
cephradine — FDA regulatory status
cephradine (VELOSEF) regulatory status in the United States is tracked from public FDA records and cross-linked clinical and patent datasets on NovaPharmaNews. Current status: FDA approved.
Status snapshot
- Status
- FDA approved
- Brand
- VELOSEF
- Originator
- Teva Pharma GmbH
- Mechanism
- Bacterial penicillin-binding protein inhibitor
- Target
- Bacterial penicillin-binding protein
- Structured fields
- 8
Sponsor / originator context: Teva Pharma GmbH. Pipeline programs and exclusivity signals below are joined from ClinicalTrials.gov-linked projects and USPTO/EPO patent rows associated with this INN.
Pharmacology context used for competitive intelligence: Bacterial penicillin-binding protein inhibitor. Target: Bacterial penicillin-binding protein. This page is a status aggregation for professional reference — not prescribing advice.
Regional decision snapshot — FDA: approved.
Linked evidence on this spoke: 8 published clinical programs and 12 related patent records. Use the tables below for NCT identifiers, phases, and exclusivity dates; verify against primary sources before BD or medical decisions.
Regulatory timeline
| Regulator | Region | Status | Date | Source |
|---|---|---|---|---|
| FDA | United States | approved | — | Evidence |
Linked clinical programs
| Program | Phase | Sponsor | NCT |
|---|---|---|---|
| MCT8-2021-3 | Phase 3 | Rare Thyroid Therapeutics | 2024-516124-34-00 |
| Tiratricol | Phase 3 | Ultragenyx UK | NCT05579327 |
| UX007 | Phase 3 | Ultragenyx UK | NCT01993186, NCT02960217 |
| Tiratricol, Tiratricol | Phase 2 | Rare Thyroid Therapeutics | 2024-516123-13-00 |
| Triheptanoin | Phase 2 | Ultragenyx UK | NCT02036853 |
| Triheptanoin | Phase 2 | Ultragenyx UK | NCT02000960 |
| UX007 | Phase 2 | Ultragenyx UK | NCT02599961 |
| CLI-06001AA1-06 | Phase 1 | Chiesi Farmaceutici S.p.A | 2024-516475-32-00 |
Related patents
| Number | Title | Jurisdiction |
|---|---|---|
| 2026093586 | COMBINAISON D'UN INHIBITEUR DE L'ALDOSTÉRONE SYNTHASE (ASI) ET D'UN INHIBITEUR DU CO-TRANSPORTEUR SODIUM-GLUCOSE DE TYPE 2 (SGLT2I) DESTINÉE À ÊTRE UTILISÉE DANS DES MÉTHODES VISANT À RÉDUIRE LE RISQUE D'ÉVÉNEMENTS CARDIOVASCULAIRES ET D'INSUFFISANCE CARDIAQUE CHEZ UN SUJET | WO |
| 12383566 | Inhibition of SLC transporter activity or expression to attenuate anthracycline-induced cardiotoxicity | US |
| 12365659 | Non-polyamine based polyamine transport inhibitors and their use in the treatment of human cancers | US |
| 12350510 | Magnetic microwires for energy-transporting biomedical applications | US |
| 12336835 | Neuromodulation to target glucose transporter and/or incretin pathways | US |
| 12329780 | Acute and chronic mitochondrial electron transport chain dysfunction treatments and graphenic materials for use thereof | US |
| 12291508 | Hydrazide containing nuclear transport modulators and uses thereof | US |
| 12247973 | Plasma membrane citrate transporter for use in the diagnosis and treatment of cancer | US |
| 12173306 | Codon-optimized reduced-size ATP7A CDNA and uses for treatment of copper transport disorders | US |
| 12152270 | Neurotransmitter transport in probiotics | US |
| 12060362 | Inhibitors of glucose transporters (GLUTs) | US |
| 12029577 | Neuromodulation to target glucose transporter and/or incretin pathways | US |
Related hubs
FAQ
What is the FDA approval status of cephradine?
cephradine currently shows FDA approved in our United States regulatory index. Confirm on the official FDA label or EPAR before clinical or commercial use.
Where does NovaPharmaNews get cephradine regulatory data?
Status fields are joined from public sources (openFDA / EMA / regional agencies), ClinicalTrials.gov-linked programs, and patent registries. See /about/data-sources for attribution.
How many clinical programs are linked to cephradine?
This spoke lists 8 published programs associated with cephradine in our pipeline index.